---
url: "https://dfylegitscript.com/blog/compounded-products-and-certification-eligibility"
title: "Compounded products and certification eligibility"
description: "Selling compounded medicines does not make a telehealth business ineligible for LegitScript certification, but it does move the application into the category where the largest number of FDA warning letters in this sector have been issued, nearly all of them over how the product was described."
published: "2025-11-27T14:24:23+00:00"
modified: "2026-02-23T08:01:23+00:00"
---

# Compounded products and certification eligibility

Selling compounded medicines does not make a telehealth business ineligible for LegitScript certification, but it does move the application into the category where the largest number of FDA warning letters in this sector have been issued, nearly all of them over how the product was described.

## Key takeaways

- Selling compounded medicines does not make a business ineligible, and it does move the application into the most closely read category in this sector.
- Three structural questions and one presentational question settle eligibility: is there a real prescription, can the compounder be identified, is the preparation within its scope, and does the site describe it accurately.
- Described accurately means compounded rather than approved, and it has to hold in the ad, the quiz result and the confirmation email as well as on the product page.
- Supply status does not move the standard, because how a preparation may be described is not a function of how scarce the approved product happens to be.

The question arrives in the wrong form. Operators ask whether compounded products
can be certified, as though eligibility were the issue. They can, routinely, and
plenty of certified merchants sell them. The real question is whether your
business can describe what it sells accurately enough to survive the review that
comes with the category.

## Why the category is scrutinised

A compounded preparation is not an approved drug. It has not been reviewed by the
FDA for safety, effectiveness or quality. It exists because a prescriber
determined that an individual patient needed something the approved market does
not supply in that form.

That is a legitimate and long-standing part of medicine. It becomes a problem
when a compounded preparation is marketed as though it were the approved product
it resembles, at scale, to consumers who cannot tell the difference.

The scale of the resulting enforcement is documented. Our
[index of FDA warning letters](/research/glp-1-compounding-warning-letters)
covering compounded GLP-1 marketing lists every one of them, grouped into the
enforcement rounds they were issued in and coded by what each letter cites:
misbranding throughout, alongside approval claims, comparisons to the brand-name
product and promises of safety or effectiveness.

A certification reviewer reading a compounded product page is reading for the
same language.

## The eligibility questions that actually decide it

**Is there a genuine prescription behind each preparation?** A compounded product
supplied without an individual prescribing decision is not a marketing problem,
it is the model the certification exists to screen out.

**Can the compounder be identified and verified?** Entity, registration type,
state licensure, permitted scope. The difference between
[a traditional compounding pharmacy and an outsourcing facility](/blog/503a-versus-503b-what-legitscript-asks-about-your-compounder)
is not cosmetic and stating it wrong is a discrepancy in your own file.

**Is the preparation within what your partner may lawfully make?** Including the
ingredients, the format and the strength.

**Does your website describe it as what it is?** Compounded, not approved, not
equivalent to the brand-name product, without borrowed trial results and without
implied outcomes.

The first three are structural. The fourth is presentational, and it is where
almost all of the failures are.

## What "described accurately" means in practice

It means the word compounded appears where a patient will see it, not only in
the terms of service. It means the pharmacy is named. It means no sentence
attaches approval language to the preparation, including formulations engineered
to be read as approval without stating it.

It means comparison is handled carefully. Comparative pricing framed against a
named brand-name drug carries an equivalence implication whether or not the text
states one, and equivalence is a claim nobody has evidence for.

It means personalisation is described honestly. Where the individualisation is a
prescriber selecting among standard strengths, describing it as a bespoke
formulation makes a claim about the product rather than about the service.

The full working version of this is in
[marketing compounded products without a misbranding problem](/blog/marketing-compounded-glp-1-products-without-a-misbranding-problem),
and it applies as squarely to men's health combination products as it does to
weight management, which
[the men's health article](/blog/mens-health-and-ed-brands-under-certification-review)
covers.

## Categories that carry extra weight

Not exhaustive, but these attract the closest reading: weight management
involving compounded GLP-1 receptor agonists, hormone therapy including
testosterone and menopause products, peptides, and combination products in
men's health.

The common factor is a compounded preparation with an approved analogue that
patients recognise, which is exactly the situation where a comparison is
tempting and where it is most damaging.

## What supply status does not change

Availability of an approved product moves over time, and the rules that apply to
compounding move with it. What does not move is the marketing standard: whatever
the supply position, a compounded preparation is not an approved product and may
not be presented as one.

Brands that built copy around a particular supply situation should assume that
copy has a shelf life and should not assume the compliance position moves with
the market. Re-auditing the claims when the underlying circumstances change is
part of maintaining certification rather than part of obtaining it.

## What to do before you apply

Establish the three structural facts, prescription, compounder, scope, and write
them down. Then run the claims audit, because that is the long pole and it is
what
[disqualifies applications](/blog/what-disqualifies-a-legitscript-application) in
this category.

If you are new to the certification itself,
[what it actually is](/blog/what-is-legitscript-healthcare-certification) is the
better starting point, because the eligibility question is easier to answer once
it is clear what is being certified.

## Three questions that settle eligibility quickly

Ask these before spending time on anything else, because a no to any of them is
a conversation about the model rather than about the file.

**Does a licensed prescriber make an individual decision for every preparation
dispensed?** If the honest answer is that the decision is effectively automatic,
the problem is structural and no amount of preparation reaches it.

**Can you name the compounder and evidence its registration and scope?** If the
dispensing entity behind your fulfilment arrangement cannot be established, you
have a gap you cannot close from your side.

**Could every claim on your site survive being read by somebody who is looking
for the four sentences?** If not, the work is presentational and it is entirely
doable, but it is work and it comes before filing rather than after.

## What to expect from the review itself

Expect questions, and expect them to be about the claims rather than about the
clinical model, because the claims are what a reviewer can see without asking.
Expect the pharmacy documentation to be requested if it was not supplied.

And expect the review to look at pages you had forgotten: the old landing page
variant still receiving traffic, the email sequence written by somebody who has
left, the affiliate creative you never approved. Those are the three places the
sentence you removed from the product page usually still lives, and they are
cheap to sweep before submission and expensive to discover during a review.

## Frequently asked questions

### Can a business selling compounded medicines be certified?

Yes, and many are. What the category brings is a closer review, particularly of the marketing claims, because compounded preparations are not approved products and the language that implies otherwise is the most cited issue in FDA enforcement in this sector.

### Does the certification approve my compounded product?

No. Certification assesses the website and the business against a private standard. It says nothing about the product's safety, effectiveness or quality, and it is not a substitute for approval, which compounded preparations do not have.

### We stopped comparing to the brand-name drug in our ads. Is that enough?

Only if the comparison is gone everywhere. The same claim usually survives in quiz result screens, email sequences, support macros and affiliate creative, all of which are reachable by a reviewer.

## Disclaimer

LegitScript is a trademark of LegitScript LLC. VeriScripts is an independent application-preparation service. It is not affiliated with, endorsed by, or certified by LegitScript LLC, and claims no sponsorship or partnership with it. We prepare, submit, and manage the application; LegitScript alone decides whether certification is granted. "LegitScript" is used here only to name the certification these applications are for.